Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis.
In this open-label, randomized, multiple-dose, two-treatment crossover study, 24 postmenopausal women with moderate to severe atrophic vaginitis received 0.3 mg conjugated estrogens daily for 14 days: 7 days orally (0.3 mg tablet) and 7 days vaginally (0.5 g cream). Steady-state plasma concentrations of E2 and estrone were one-third lower after vaginal versus oral administration of conjugated estrogens.
Dorr
Mary Beth
MB
Pfizer, Collegeville, Pennsylvania 19426, USA. marybethdorr@yahoo.com
Nelson
Anita L
AL
Mayer
Philip R
PR
Ranganath
Radhika P
RP
Norris
Paul M
PM
Helzner
Eileen C
EC
Preston
Richard A
RA
D000282:Administration, Intravaginal; D000284:Administration, Oral; D000368:Aged; D001284:Atrophy / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D004970:Estrone / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D009994:Osmolar Concentration; D014621:Vagina / Q000187:drug effects / Q000473:pathology*; D014622:Vaginal Creams, Foams, and Jellies; D014627:Vaginitis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism
D004966:Estrogens, Conjugated (USP); D014622:Vaginal Creams, Foams, and Jellies; D004970:Estrone; D004958:Estradiol